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Background: Stroke is a multi-factorial disease and influenced by both genetic and environmental factors. The
purpose of the present case control study was to check the relationship between beta-2 adrenergic receptor
(ADRB2) polymorphism and ischemic stroke in North Indian Population.
Methods: In a hospital based case control study, patients with ischemic stroke and control subjects from
outpatient department and neurology ward of All India Institute of Medical Sciences New Delhi. Genotyping was
performed by using Polymerase chain reaction–Restriction fragment length polymorphism. Frequency distributions
of genotypes and alleles were compared between cases and controls using multivariate logistic regression.
Results: In this study, 224 patients and 224 age-and sex-matched control subjects were recruited. Mean age of
cases and controls were 53.9 ± 13.4 and 53.6 ± 12.9 years respectively. Multivariate logistic regression analysis
showed an independent association between Gln27Glu polymorphism and large vessel stroke (LVD) under a
recessive model of inheritance (OR 3.9; 95% CI 1.3 to 11). An age-stratified analysis, suggested independent
association between Gln27Glu polymorphism and ischemic stroke, large vessel disease and small vessel disease
stroke who had onset of disease at an older age.
Conclusions: The findings of the present study suggest that Gln27Glu polymorphism of the ADRB2 gene may
confer higher risk of large vessel disease stroke in a North Indian population. Prospective studies with larger sample
size are required for independent validation.Background
Stroke is the second most common cause of death after
ischemic heart disease [1], but, it ranks first in the Asian
regions that have the highest population in the world
[2]. There are 16.9 million incident stroke cases worldwide,
twice as many stroke survivors, and 5.9 million deaths
from stroke [2]. Incidence of stroke in South Asian coun-
tries have increased by more than 100% while this is de-
ceased by 42% in developed European courtiers in last four
decade [3]. World Health Organisation estimates suggest* Correspondence: amits52003@gmail.com; kp0704@gmail.com
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unless otherwise stated.that by 2050, 80 percent of stroke cases in the world would
occur in low and middle income countries, mainly India
and China [4].
Stroke is a multifactorial, polygenic disorder, influenced
by both environmental and genetic factors. There are sev-
eral risk factors has been discovered for stroke, such as
hypertension, diabetes, smoking, dyslipidemia etc., how-
ever these risk factors do not explain why some individual
are more susceptible to these environmental determinants
in comparison to others with same given risk factors [5].
A growing body of evidence, suggesting that genetic vari-
ant may predispose to developing stroke [6]. The beta-2
adrenergic receptor, coded by an intronless gene on the
long arm of chromosome 5q31–32 (Figure 1) and foundLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Location of beta-2 receptor in chromosome 5q31–32.
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family of G protein-coupled receptors that generally
modulate action of catecholamine by an increase in level
of secondary messenger cyclic AMP. It has been shown
that agonist-independent, G-protein coupled receptor ac-
tivity regulates anterior-posterior targeting of olfactory
sensory neurons [7]. Reduced expression of beta-2 ad-
renergic receptor contributes to the age- related deteri-
oration of glucose tolerance [8]. It is broadly recognized
that the beta-blocker therapy shows better response in
younger patients than hospitalized senescent patients
[9]. Cathecolamine-induced adenylate cyclase activity has
been shown to decrease during ageing in human lym-
phocytes [10,11]. The age-related deterioration in beta-
adrenergic receptor function and subsequent cyclic AMP
generation [12] that is a common factor underlying ath-
erosclerosis, vascular insufficiency and hypertension [13]
and these mechanisms are believed to confer increased































Abbreviation: BAR beta adrenergic receptor.Cyclic AMP is also a possible target for prevention and
treatment of atherosclerosis [15]. It is reported in the re-
cent year that these polymorphisms are related to many
kinds of clinical diseases such as asthma, hypertension,
diabetes, heart diseases [16]. In the present study, we ex-
amined the relationship of Arg16Gly and Gln27Glu poly-
morphisms of beta-2 adrenergic receptor (Figure 2) as a
risk factor for ischemic stroke in the North India in order
to facilitate early diagnosis of the susceptible population
and prevention of ischemic stroke.
Methods
During this study, 224 patients with ischemic stroke and
224 control subjects were enrolled from the ward and
outpatient department of Neurology, All India Institute
of Medical Sciences (AIIMS), New Delhi, India from the
period of February 2010 to April 2012. Ischemic stroke
was defined as rapidly developing clinical signs of focal
(or global) disturbance of cerebral function, with symp-
toms lasting more than 24 hours or longer or leading to
death, with no apparent cause other than of vascular ori-
gin [17]. Stroke is a heterogeneous phenotype, therefore,
analysis based on specific stroke cause in important in
genetic association studies, therefore, we used TOAST
criteria to determine stroke aetiology [18], which include
large vessel stroke which occurs usually due to athero-
sclerosis or occlusion of major brain artery or branch
cortical artery and small vessel stroke which occur due
to the involvement of small perforating end arteries within
the brain. All subjects underwent standardized clinical eval-
uations. The study was approved by the All India Institute
of Medical Sciences, New Delhi ethics committee (Ref No.
P-02/06.10.2008). Informed consent was obtained from
each patient/control subject or from the relatives or a legal
representative in the case of critically disabled patients. In-
clusion and exclusion criteria for cases and control subjects
are same as earlier published article by our team [19]. Defi-
nitions of variables are same as in the published study [5].
Sample size
Sample size calculation was based on parameters of the
study reported by Stanzione et al. [20], on beta-adrenergic
receptor polymorphism in ischemic stroke in which preva-
lence for the beta-adrenergic receptor variant Glu27Glu
genotype was 0.32 in control group and odds ratio for this
polymorphism was 1.68. Assuming 80% power and 5%
alpha, with one control per case, we obtained estimated
minimum sample size were 212. 224 patients and 224
controls were included in this study to compensate for
any loss of sample.
Genomic DNA extraction
Genomic DNA was isolated by conventional Phenol
Chloroform Method. DNA concentrations were estimated
Figure 2 Localization and characterization beta-2, adrenergic receptor polymorphism studied.
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nanodrop spectrophotometer (Gene Quant, Pharmacia,
USA) and its quality was assessed by the A260/A280 ratio.
DNA samples with a 260/280 ratio ranging from 1.5 to 1.8
were processed for PCR amplification.Detection of gene polymorphisms
Genotyping: Primers used for the amplification of Arg16-
Gly polymorphism of beta-2 adrenergic receptor is: for-
ward: 5’-CTTCTTGCTGGCACGCAAT -3’ reverse: 5’-C
CAGTGAAGTGATGAAGTAGTTGG -3’, (PCR product
length was 201 bp, restriction enzyme BsrD1; Ferments;
2.5 U for 6 h at 37°C). For determination of Gln27Glu
polymorphism, primer used were forward 5’-GAATGAG
GCTTCCAGGCGTC-3’ reverse 5’- GGCCCATGACC
AGATCAGCA-3’ (PCR product length was 356 bp;
restriction enzyme FNu4HI Fermentas; 0.5 U for 6 hTable 2 Demographic and risk factors variables of Ischemic st
S.No Variables Case Control Un
1 aAge ± SD (years) 53.9 ± 3.4 53.6 ± 12.9
2 Male/Female 183/41 183/41
3 Hypertension n (%) 138 (62%) 48 (21%)
4 Smoking n (%) 98 (44%) 53 (24%)
5 Diabetes n (%) 67 (31%) 35 (16%)
6 Migraine n (%) 20 (9%) 15 (6%)
7 Dyslipidemia n (%) 96 (43%) 37 (17%)
8 FHS n (%) 48(21.5) 15(6.9)
aAge of stroke patients at the time of onset; SD, standard deviation; FHS, family his
not significant).at 37°C). The restriction products were separated by elec-
trophoresis in 2.5% agarose gels and visualized in UV
light. Gel Images were documented by using gel doc.Statistical analyses
Allele frequencies were compared using the Chi square
test. The conditional logistic regression model was used to
estimate Odds ratio (OR) and 95% confidence intervals
(CIs) for association of beta-1 receptor polymorphisms
with ischemic stroke. Multivariate logistic regression was
used to control the confounding effect of demographic
and risk factor variables. Tests were considered signifi-
cant at P < 0.05. The chi square test was used to deter-
mine the frequency distribution of genotypes, were in
accordance with Hardy-Weinberg equilibrium (HWE).
Data were analyzed using the SPSS statistical package,
version 17.0 (SPSS, Chicago, IL, USA).roke patients and controls
adjusted OR (95% CI), p value *Adjusted OR (95% CI), p value
Matched Matched
Matched Matched
5.8 (3.8 to 8.8), < 0.001 6.6 (3.4 to 12.9), <0.001
2.4 (1.6 to 3.6), < 0.001 2.8 (1.5 to 5.2), 0.001
2.4 (1.5 to 3.8), 0.001 1.5 (0.85 to 2.8), 0.15
1.3 (0.67 to 2.8), 0.37, NA
3.6 (2.3 to 5.7), < 0.001 3.8 (1.9 to 7.7), <0.001
3.7 (2 to 6.8), < 0.001 5.2 (2.3 to 11.5), <0.001
tory of stroke; NA, Not applicable (Excluded from the model as statistically
Table 3 Association between Arg16Gly and Gln27Glu polymorphisms of beta -2 adrenergic receptor and Ischemic
stroke
Polymorphism N Sample Genotype
distribution (%)
HWE Recessive Dominant Sample Allele
distribution (%)
OR [95% CI],
P value Adjusted Adjusted P value
OR [95% CI], OR [95% CI],
Arg16Gly Arg/Arg Arg/Gly Gly/Gly P value P value Arg Gly
224 IS 21 53 26 0.39 1.5 1.5 IS 47 53 1.3 [0.7 to 2.3],
224 Controls 28 52 20 0.43 [0.76 to 3.2], [0.74 to 3.3], Control 54 46 0.32
0.21 0.23
76 LVD 20 55 25 0.34 1.2 0.97 LVD 47 53 1.3 [0.7 to 2.3],
224 Control 28 52 20 0.43 [0.21 to 7.6,] [0.07 to 13], Control 54 46 0.32
0.78 0.98
78 SVD 19 50 31 0.88 2.9 2.4 SVD 44 56 1.4 [0.8 to 2.6],
224 Control 28 52 20 0.43 [0.71 to 12], [0.43 to 13], Control 54 46 0.15
0.13 0.31
Gln27Glu Gln/Gln Gln/Glu Glu/Glu Gln Glu
224 IS 44 40 16 0.07 2.8 1.5 IS 64 36 1.6 [0.91 to 3.1],
224 Controls 55 39 6 0.59 [0.98 to 8.1], [0.91 to 2.7], Control 75 25 0.09
0.05 0.10
76 LVD 47 35 18 0.04 3.9 1.5 LVD 64 36 1.6 [0.91 to 3.1],
224 Control 55 39 6 0.59 [1.3 to 11], [0.81 to 2.9], Control 75 25 0.09
0.01 0.18
78 SVD 42 45 13 0.87 0.97 1.4 SVD 65 35 1.6 [ 0.87 to 2.9],
224 Control 55 39 6 0.59 [0.15 to 6.1] [0.44 to 5], Control 75 25 0.12
0.98 0.51
Abbreviations: IS ischemic stroke, OR odds ratio, CI confidence interval, LVD large vessel stroke, SVD small vessel stroke.
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Demographic and risk factor variables in cases and con-
trols are given in (Table 2). Multivariate analysis did not
show a significant association between Arg16Gly poly-
morphism and ischemic stroke (Table 3 and Additional
file 1: Table S1). Analysis stratified by hypertension and
age showed weak associations of Arg16Gly polymorphism
among some of subgroups (Additional file 1: Table S2).
Borderline significance was observed between Gln27Glu
polymorphism of beta-2 AR and ischemic stroke (OR, 2.8;
95% CI, 0.98 to 8.1; P = 0.05) under recessive model ofTable 4 Haplotype frequencies of beta-2 adrenergic
receptor Arg16Gly and Gln27Glu polymorphisms
Haplotype Case n (%) Control n (%) OR (95% CI) P Value
Arg16-Gln27 115 (25.7) 205 (45.7) Reference
Arg16-Glu27 97 (21.5) 38 (8.5) 4.5 (2.9 to 7) <0.001
Gly16-Glu27 172 (38.4) 129 (28.8) 2.3 (1.7 to 3.2) <0.001
Gly16-Gln27 64 (14.4) 76 (17) 1.5 (1.001 to 2.2) 0.04
Total 448 448
Abbreviations: OR odds ratio, CI 95% confidence interval, Gly Glycine, Arg
Arginine, Glu Glutamic acid, Gln Glutamine.inheritance (Table 3). Distribution of genotypic and al-
lelic frequencies of polymorphism at Gln27Glu (SNP 79
C>G) position of beta-2 adrenergic receptor gene in
controls and ischemic stroke and its subtypes are given
in Additional file 1: Table S3. Significant association was
observed between Gln27Glu polymorphism and LVD
stroke (OR, 3.9; 95% CI, 1.3 to 11; P = 0.01) in adjusted
analysis under the recessive model of inheritance (Table 3).
Age stratified analysis, showed an independent significant
association between Gln27Glu variant and risk of overall
ischemic stroke, LVD stroke and SVD stroke, assuming
both recessive and dominant model of inheritance only in
the patients, those who had late onset (>50 years) of
disease (Additional file 1: Table S4). Individuals carrying
haplotype Arg16-Glu27 were found to be 4.5 fold higher
risk of ischemic stroke as compared to control (OR, 4.5;
95% CI, 2.9 to 7). Gly16-Glu27 haplotype was significantly
associated with risk of ischemic stroke (OR, 2.3; 95% CI,
1.7 to 3.2) (Table 4).
Discussion
In this hospital based case control study, a common
functional polymorphism at Gln27Glu position of beta-2
Table 5 Frequency distribution of variant allele of Arg16Gly and Gln27Glu polymorphism in few of different ethnic
regions
Study design Year Allele frequency (%) Population Sample size Condition Reference
Gly16 Glu27 Case/control
Case/control Case/control
Case control 1998 NA 0.43/0.36 Denmark 156/205 Obesity [21]
Case control 2006 NA 0.26/0.15 Saudi Arabia 773/528 Coronary artery disease [22]
Case control 2007 0.66/0.65 0.57/0.48 Italy 294/286 Stroke [20]
Case control 2011 0.46/0.43 0.17/0.14 Chinese 238/265 Asthma [23]
Case control 2012 0.49/0.39 0.07/0.12 Malaysia 50/50 Hypertension [24]
Case control 2005 0.40/0.38 0.43/0.41 California 194/819 Myocardial infarction [25]
Cohort study 2009 0.58 0.29 Brazil 501 Heart Failure [26]
Meta-analysis 2012 0.47/0.46 0.48/0.17 Asian 1097/844 Chronic obstructive
pulmonary disease
[27]
Meta-analysis 2012 0.61/0.62 0.41/0.40 Caucasian 727/850 Chronic obstructive
pulmonary disease
[27]
Case control 2012 0.60/0.65 0.27/0.30 North Indian 410/414 Asthma [28]
Case control 2014 0.52/0.58 0.47/0.23 North Indian 106/106 Hemorrhagic Stroke [29]
Present study 2014 0.53/0.46 0.36/0.25 North Indian 224/224 Ischemic Stroke Present study
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increased risk of LVD stroke.
The present study is the first study, up to the best of
our knowledge, showing the association of Arg16Gly
and Gln27Glu polymorphisms of beta-2 adrenergic recep-
tor with ischemic stroke in Asian population. Frequency
distribution of variant alleles of Arg16Gly and Gln27Glu
polymorphisms of beta-2 adrenergic receptors in our
study are consistent with the other previously reported
studies (Table 5).
In vitro studies have shown higher agonist induced
desensitization for Gly16 variant in comparison to Arg16
variant after the administration of isoprenaline which is a
nonselective beta adrenergic agonist [30]. In vitro study
[31] has indicated that Glu27 variant produces a higher de-
gree of responsiveness to adrenergic agonist with resistance
to down regulation relative to wild type allele, however,
strong linkage disequilibrium between codon 16 and codon
27 and there is greater probability that subjects who are
carrying Glu27Glu genotype are mostly homozygous for
Gly16 allele than Arg16 [32]. Our study also showed simi-
lar linkage disequilibrium. Gly16-Glu27 haplotype showed
enhanced receptor down regulation after exposure to iso-
prenaline when compared with Arg16-Glu27 [30]. Due to
strong linkage disequilibrium, it has been suggested that
subject carrying Gly16-Glu27 haplotype may have greater
down regulation and desensitization as compared to
Arg16 allele [30,33]. Down regulation of this receptor
may lead to decrease in concentration of cyclic AMP in
the vascular smooth muscle, lungs, kidney, and sympa-
thetic terminal. This decrease in cyclic AMP leads tomodulation of atherosclerosis, recruitment of reactive
oxygen species, and recruitment of circulating mono-
cytes to the artery wall and their differentiation into
macrophage foam cell, by controlling the expression of
proinflammatory and anti-inflammatory interleukin [15].
By these mechanisms, beta-2 adrenergic receptor gene
polymorphisms might influence the genetic predisposition
to ischemic stroke. Several studies have shown the inde-
pendent association of Gln27Glu polymorphism of beta-2
adrenergic receptor gene polymorphism with a number of
diseases like obesity [34,35], dyslipidemia [36], myocardial
infarction [16], diabetes [37]. Few studies have addressed
the association of beta-2 receptor polymorphism with is-
chemic stroke and both positive and negative associations
have been reported. A case control study, reported from
Italy, indicated a positive association between Gln27Glu
polymorphism and Ischemic stroke [20]. A previous study
by Heckbert et al., failed to show significant association of
beta-2 adrenergic receptor variant with the incidence of
stroke [38]. A prospective cohort study included 25225
women showed that the different haplotypic combin-
ation of beta receptor gene variant did not affect the
incidence of ischemic stroke in women [39]. A case con-
trol study reported by Zhao et al. did not find significant
association of Gln27Glu polymorphism with risk of is-
chemic stroke, however, higher frequency of variant
Glu27 allele in ischemic stroke patients (0.11) than con-
trols (0.07) has been observed [40]. In all the published
case control studies (three), the frequency of the risk
allele (Glu27) was higher in cases as compared to con-
trols. Our study also indicated a significant association
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associated with large vessel disease.
Hypertension is a most important and common risk fac-
tor for stroke. A meta-analysis published by Lou Y, et al.,
[41] showed significant association between Arg16Gly
polymorphism and risk of hypertension under a domin-
ant model in a subgroup of mixed African (OR, 1.18,
95% CI, 1.01 to 1.87, P = 0.04). This meta-analysis also
indicated the significant association between Gln27Glu
polymorphism and hypertension under a dominant
model of inheritance (OR, 1.38; 95% CI, 1.02 to 1.86)
[41]. Other polymorphisms such as on gene CaMK4
(calcium/calmodulin-dependent kinase 4) which has a
role in regulation of vascular tone also have been shown
to be associated with hypertension [42]. A previous
study has demonstrated that more than 85% patients
with CHD have at least 1 of five modifiable risk factors
(hypertension, diabetes, and hypercholesterolemia, smok-
ing and family history) [43,44]. A previous study indicated
that the P (A2) polymorphism is a genetic determinant
of ischemic stroke in a high-risk hypertensive popula-
tion [45]. Our analysis, stratified by hypertension indi-
cates that Glu27 variant is associated with both the
hypertensive and non-hypertensive stroke subjects and
shows a similar pattern of associations in both the
groups (Additional file 1: Table S4).
The age-related decline in beta-adrenergic receptor
function and subsequent cyclic AMP generation [12] is
a common factor underlying atherosclerosis, vascular
insufficiency and hypertension [13]. A study has shown
that age-associated decline in beta-adrenergic receptor
sensitivity in the cardiovascular system [46]. Our age-
stratified analysis, showed significant associations of
Gln27Glu polymorphism in only those patients who had
onset of disease at late (>50 years) stage. During old age
conventional risk factors of stroke becomes more preva-
lent and it is possible that Glu27 variant may interact at
later stages of age with other conventional risk factors
that cause stroke.
In the present study, individuals who had Arg16-Glu27
haplotype were found to have a higher risk of ischemic
stroke. This association shows the additive effects of both
the alleles and may have enhanced combined impact of
ischemic stroke risk. The present study suggests that
Haplotype Gly16-Glu27 was most prevalent haplotype
and significantly associated with risk of ischemic stroke.
This is consistent with finding of the study reported by
Stanzione et al. [20].
Studies have shown that there is a relationship be-
tween the effectiveness of beta-blocker treatment and
beta adrenergic receptor polymorphism [47]. Further
studies are required to check the significance of beta
blocker treatment and stroke prevention in carrier of
beta-adrenergic receptor polymorphism.Limitation of the study
The sample size of the present study might not be large
enough to detect small effects of low penetrance SNPs.
Each susceptible polymorphism may only contribute to
mild effect, thus the analysis of single SNP could be am-
biguous by unstudied polymorphisms and environmental
factors that influences the phenotype. Borderline devi-
ation from HWE was observed in the distribution of
genotypes in patients with LVD stroke. We cannot com-
pletely exclude the effects of residual confounding at-
tributable to the measurement error in the assessment
of confounding factors. In the present study, the num-
bers of male patients were more than double the num-
ber of female patients, which substantiates that results
of this study may be applied to male ischemic stroke
populations.Conclusion
In conclusion, this study provides evidence that the
presence of Arg16-Glu27 haplotype of beta-2 adrenergic
receptor in the subjects might confer increased risk of
developing ischemic stroke. Gln27Glu polymorphism
may confer increased risk for developing stroke associated
with large vessel. Identification of a subgroup of patients,
who are carrier of beta-adrenergic receptor polymorph-
ism, may have implication for planning their future treat-
ment strategies. Prospective studies with larger sample
size are required for independent validation.Additional file
Additional file 1: Table S1. Distribution of genotypic and allelic
frequencies of polymorphism at Arg16Gly (SNP 46 A>G) position of
beta-2 adrenergic receptor gene in controls and ischemic stroke and its
subtypes. Table S2. Analysis stratified by hypertension and age for
association of polymorphism at Arg16Gly (SNP 46 A>G) position of
beta-2 adrenergic receptor gene with ischemic stroke and its subtypes.
Table S3. Distribution of genotypic and allelic frequencies of polymorphism
at Gln27Glu (SNP 79 C>G) position of beta-2 adrenergic receptor gene in
controls and ischemic stroke and its subtypes. Table S4. Analysis stratified
by hypertension and age for association of polymorphism at Gln27Glu
(SNP79C>G) position of beta-2 adrenergic receptor gene with ischemic
stroke and its subtypes.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
AK has participated in the writing of manuscript, conception, design and
conduct of the study. KP has participated in the design, analysis and
interpretation of data. MT, MVPS and SV have participated in the conception
and design of the study. All authors read and approved the final manuscript.Acknowledgement
Funding support of the study was obtained from the Indian Council of
Medical Research, Government of India.
Kumar et al. BMC Research Notes 2014, 7:396 Page 7 of 8
http://www.biomedcentral.com/1756-0500/7/396Author details
1Department of Neurology, Room No. 704, Neurosciences Centre, All India
Institute of Medical Sciences, Ansari Nagar, New Delhi, India. 2Department of
Neurobiochemistry, All India Institute of Medical Sciences, New Delhi, India.
Received: 21 October 2013 Accepted: 13 June 2014
Published: 25 June 2014
References
1. World Health Organisation.int [internet]: WHO media centre. [Updated July
2013]. Available from: https://apps.who.int/infobase/Mortality.aspx.
2. Davis S, Norrving B: Organizational update: world stroke organization.
Stroke J Cereb Circ 2014, 45(5):e84.
3. Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V: Worldwide
stroke incidence and early case fatality reported in 56 population-based
studies: a systematic review. Lancet Neurol 2009, 8(4):355–369.
4. World Health Organisation.int [internet]: WHO media centre. [Updated July
2013]. Available from: https://apps.who.int/infobase/Indicators.aspx.
5. Kumar A, Sagar R, Kumar P, Sahu JK, Grover A, Srivastava AK, Vivekanandhan S,
Prasad K: Identification of genetic contribution to ischemic stroke by
screening of single nucleotide polymorphisms in stroke patients by using a
case control study design. BMC Neurol 2013, 13(1):136.
6. Hassan A, Markus HS: Genetics and ischaemic stroke. Brain J Neurol 2000,
123(Pt 9):1784–1812.
7. Nakashima A, Takeuchi H, Imai T, Saito H, Kiyonari H, Abe T, Chen M,
Weinstein LS, Yu CR, Storm DR, Nishizumi H, Sakano H: Agonist-independent
GPCR activity regulates anterior-posterior targeting of olfactory sensory
neurons. Cell 2013, 154(6):1314–1325.
8. Santulli G, Lombardi A, Sorriento D, Anastasio A, Del Giudice C, Formisano P,
Béguinot F, Trimarco B, Miele C, Iaccarino G: Age-related impairment in
insulin release: the essential role of β(2)-adrenergic receptor.
Diabetes 2012, 61(3):692–701.
9. Greenblatt DJ, Koch-Weser J: Adverse reactions to propranolol in
hospitalized medical patients: a report from the Boston Collaborative
Drug Surveillance Program. Am Heart J 1973, 86(4):478–484.
10. Krall JF, Connelly M, Tuck ML: Evidence for reversibility of age-related
decrease in human lymphocyte adenylate cyclase activity. Biochem
Biophys Res Commun 1981, 99(3):1028–1034.
11. Santulli G, Iaccarino G: Pinpointing beta adrenergic receptor in ageing
pathophysiology: victim or executioner? Evidence from crime scenes.
Immun Ageing A 2013, 10(1):10.
12. Schutzer WE, Mader SL: Age-related changes in vascular adrenergic
signaling: clinical and mechanistic implications. Ageing Res Rev 2003,
2(2):169–190.
13. Vu T-HT, Stamler J, Liu K, McDermott MM, Lloyd-Jones DM, Pirzada A,
Garside DB, Daviglus ML: Prospective relationship of low cardiovascular risk
factor profile at younger ages to ankle-brachial index: 39-year follow-up–
the Chicago Healthy Aging Study. J Am Heart Assoc 2012, 1(6):e001545.
14. Iwamoto Y, Ohishi M, Yuan M, Tatara Y, Kato N, Takeya Y, Onishi M,
Maekawa Y, Kamide K, Rakugi H: β-Adrenergic receptor gene
polymorphism is a genetic risk factor for cardiovascular disease: a cohort
study with hypertensive patients. Hypertens Res Off J Jpn Soc Hypertens
2011, 34(5):573–577.
15. Fantidis P: The role of intracellular 3’5’-cyclic adenosine monophosphate
(cAMP) in atherosclerosis. Curr Vasc Pharmacol 2010, 8(4):464–472.
16. Yilmaz A, Kaya MG, Merdanoglu U, Ergun MA, Cengel A, Menevse S:
Association of beta-1 and beta-2 adrenergic receptor gene polymorphisms
with myocardial infarction. J Clin Lab Anal 2009, 23(4):237–243.
17. The World Health Organization: MONICA Project (monitoring trends and
determinants in cardiovascular disease): a major international
collaboration. WHO MONICA Project Principal Investigators. J Clin
Epidemiol. 1988, 41(2):105–114.
18. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL,
Marsh EE 3rd: Classification of subtype of acute ischemic stroke.
Definitions for use in a multicenter clinical trial. TOAST. Trial of Org
10172 in Acute Stroke Treatment. Stroke J Cereb Circ. 1993, 24(1):35–41.
19. Kumar A, Vivekanandhan S, Srivastava A, Tripathi M, Padma Srivastava MV,
Saini N, Kumar P, Prasad K: Association between angiotensin converting
enzyme gene insertion/deletion polymorphism and ischemic stroke in
north Indian population: a case-control study and meta-analysis.
Neurol Res. 2014, 12:1743132814Y0000000335.20. Stanzione R, Di Angelantonio E, Evangelista A, Barbato D, Marchitti S,
Zanda B, Pirisi A, Quarta G, Volpe M, Rubattu S: Beta2-adrenergic receptor
gene polymorphisms and risk of ischemic stroke. Am J Hypertens 2007,
20(6):657–662.
21. Echwald SM, Sørensen TI, Tybjaerg-Hansen A, Andersen T, Pedersen O: Gln27Glu
variant of the human beta2-adrenoreceptor gene is not associated with
early-onset obesity in Danish men. Diabetes 1998, 47(10):1657–1658.
22. Abu-Amero KK, Al-Boudari OM, Mohamed GH, Dzimiri N: The Glu27
genotypes of the beta2-adrenergic receptor are predictors for severe
coronary artery disease. BMC Med Genet. 2006, 7:31.
23. Fu W-P, Zhao Z-H, Zhong L, Sun C, Fang L-Z, Liu L, Zhang JQ, Wang L,
Shu JK, Wang XM, Dai LM: Relationship between polymorphisms in the 5’
leader cistron, positions 16 and 27 of the adrenergic β2 receptor gene
and asthma in a Han population from southwest China. Respirol Carlton
Vic 2011, 16(8):1221–1227.
24. Atia AE, Norsidah K, Nor Zamzila A, Rafidah Hanim M, Samsul D, Aznan MA,
Rashidah AR, Norlelawati AT: Preliminary study on association of
beta2-adrenergic receptor polymorphism with hypertension in
hypertensive subjects attending Balok Health Centre. Kuantan. Med J
Malaysia. 2012, 67(1):25–30.
25. Zee RYL, Cook NR, Reynolds R, Cheng S, Ridker PM: Haplotype analysis of
the beta2 adrenergic receptor gene and risk of myocardial infarction in
humans. Genetics 2005, 169(3):1583–1587.
26. Mansur AJ, Fontes RS, Canzi RA, Nishimura R, Alencar AP, de Lima ACP,
Krieger JE, Pereira AC: Beta-2 adrenergic receptor gene polymorphisms
Gln27Glu, Arg16Gly in patients with heart failure. BMC Cardiovasc Disord
2009, 9:50.
27. Niu L-M, Liang Y, Xu M, Zhang Y-Y, Zhang Y, He B: Effect of polymorphisms
in the β2-adrenergic receptor on the susceptibility and pulmonary
function of patients with chronic obstructive pulmonary disease: a meta
analysis. Chin Med J (Engl) 2012, 125(12):2213–2218.
28. Birbian N, Singh J, Jindal SK, Singla N: Association of β(2)-adrenergic
receptor polymorphisms with asthma in a North Indian population.
Lung 2012, 190(5):497–504.
29. Kumar A, Prasad K, Tripathi M, Padma Srivastava MV, Vivekanadhan S:
Association of genetic polymorphisms at beta-adrenergic receptor with
risk of intracerebral hemorrhagic stroke in North Indian population: A
case control study. Neurol India 2014, 62:183–188.
30. Green SA, Turki J, Innis M, Liggett SB: Amino-terminal polymorphisms of
the human beta 2-adrenergic receptor impart distinct agonist-promoted
regulatory properties. Biochemistry (Mosc) 1994, 33(32):9414–9419.
31. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ: The
effect of common polymorphisms of the beta2-adrenergic receptor on
agonist-mediated vascular desensitization. N Engl J Med 2001,
345(14):1030–1035.
32. Dewar JC, Wheatley AP, Venn A, Morrison JF, Britton J, Hall IP:
Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but
are not associated with asthma in an adult population. Clin Exp Allergy J
Br Soc Allergy Clin Immunol 1998, 28(4):442–448.
33. Forleo C, Resta N, Sorrentino S, Guida P, Manghisi A, De Luca V, Romito R,
Iacoviello M, De Tommasi E, Troisi F, Rizzon B, Guanti G, Rizzon P,
Pitzalis MV: Association of beta-adrenergic receptor polymorphisms and
progression to heart failure in patients with idiopathic dilated
cardiomyopathy. Am J Med 2004, 117(7):451–458.
34. Large V, Hellström L, Reynisdottir S, Lönnqvist F, Eriksson P, Lannfelt L,
Arner P: Human beta-2 adrenoceptor gene polymorphisms are highly
frequent in obesity and associate with altered adipocyte beta-2
adrenoceptor function. J Clin Invest 1997, 100(12):3005–3013.
35. Lange LA, Norris JM, Langefeld CD, Nicklas BJ, Wagenknecht LE, Saad MF,
Bowden DW: Association of adipose tissue deposition and beta-2 adrenergic
receptor variants: the IRAS family study. Int J Obes 2005, 29(5):449–457.
36. Ehrenborg E, Skogsberg J, Ruotolo G, Large V, Eriksson P, Arner P,
Hamsten A: The Q/E27 polymorphism in the beta2-adrenoceptor gene is
associated with increased body weight and dyslipoproteinaemia involving
triglyceride-rich lipoproteins. J Intern Med 2000, 247(6):651–656.
37. Carlsson M, Orho-Melander M, Hedenbro J, Groop LC: Common variants in
the beta2-(Gln27Glu) and beta3-(Trp64Arg)–adrenoceptor genes are
associated with elevated serum NEFA concentrations and type II
diabetes. Diabetologia 2001, 44(5):629–636.
38. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS,
Tang Z, Durda JP, Kronmal RA, Tracy RP: Beta2-adrenergic receptor
Kumar et al. BMC Research Notes 2014, 7:396 Page 8 of 8
http://www.biomedcentral.com/1756-0500/7/396polymorphisms and risk of incident cardiovascular events in the elderly.
Circulation 2003, 107(15):2021–2024.
39. Schürks M, Kurth T, Ridker PM, Buring JE, Zee RYL: Association between
polymorphisms in the beta2-adrenergic receptor gene with myocardial
infarction and ischaemic stroke in women. Thromb Haemost 2009,
101(2):351–358.
40. Zhao N, Liu X, Wang Y, Liu X, Li J, Yu L, Ma L, Wang S, Zhang H, Liu L, Zhao J,
Wang X: Association of inflammatory gene polymorphisms with ischemic
stroke in a Chinese Han population. J Neuroinflammation. 2012, 9:162.
41. Lou Y, Liu J, Huang Y, Liu J, Wang Z, Liu Y, Li Z, Li Y, Xie Y, Wen S: A46G
and C79G polymorphisms in the β2-adrenergic receptor gene (ADRB2)
and essential hypertension risk: a meta-analysis. Hypertens Res Off J Jpn
Soc Hypertens 2010, 33(11):1114–1123.
42. Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S,
Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G: CaMK4
Gene Deletion Induces Hypertension. J Am Heart Assoc 2012, 1(4):e001081.
43. Banack HR, Harper S, Kaufman JS: Coronary heart disease risk factors and
mortality. JAMA 2012, 307:1137–1138. author reply 1138.
44. Canto JG, Kiefe CI, Rogers WJ, Peterson ED, Frederick PD, French WJ,
Gibson CM, Pollack CV Jr, Ornato JP, Zalenski RJ, Penney J, Tiefenbrunn AJ,
Greenland P: Number of coronary heart disease risk factors and mortality
in patients with first myocardial infarction. JAMA J Am Med Assoc 2011,
306(19):2120–2127.
45. Lanni F, Santulli G, Izzo R, Rubattu S, Zanda B, Volpe M, Iaccarino G,
Trimarco B: The Pl(A1/A2) polymorphism of glycoprotein IIIa and
cerebrovascular events in hypertension: increased risk of ischemic stroke
in high-risk patients. J Hypertens 2007, 25(3):551–556.
46. Arribas S, Marín J, Ponte A, Balfagón G, Salaices M: Norepinephrine-induced
relaxations in rat aorta mediated by endothelial beta adrenoceptors.
Impairment by ageing and hypertension. J Pharmacol Exp Ther. 1994,
270(2):520–527.
47. Cotarlan V, Brofferio A, Gerhard GS, Chu X, Shirani J: Impact of β(1)- and
β(2)-adrenergic receptor gene single nucleotide polymorphisms on
heart rate response to metoprolol prior to coronary computed
tomographic angiography. Am J Cardiol 2013, 111(5):661–666.
doi:10.1186/1756-0500-7-396
Cite this article as: Kumar et al.: Relationship between polymorphisms in
beta -2 adrenergic receptor gene and ischemic stroke in North Indian
Population: a hospital based case control study. BMC Research Notes
2014 7:396.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
